Neurocrine Biosciences (NBIX) Short Interest Ratio & Short Volume $114.00 -0.45 (-0.39%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$113.16 -0.83 (-0.73%) As of 03/27/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Neurocrine Biosciences Short Interest DataNeurocrine Biosciences (NBIX) has a short interest of 3.29 million shares, representing 3.45% of the float (the number of shares available for trading by the public). This marks a 1.86% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.5, indicating that it would take 2.5 days of the average trading volume of 957,132 shares to cover all short positions.Current Short Interest3,290,000 sharesPrevious Short Interest3,230,000 sharesChange Vs. Previous Month+1.86%Dollar Volume Sold Short$364.37 millionShort Interest Ratio2.5 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares99,704,000 sharesShort Percent of Float3.45%Today's Trading Volume621,381 sharesAverage Trading Volume957,132 sharesToday's Volume Vs. Average65% Short Selling Neurocrine Biosciences? Sign up to receive the latest short interest report for Neurocrine Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNBIX Short Interest Over TimeNBIX Days to Cover Over TimeNBIX Percentage of Float Shorted Over Time Remove Ads Neurocrine Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20253,290,000 shares $364.37 million +1.9%3.4%2.5 $110.75 2/28/20253,230,000 shares $383.46 million +6.3%3.4%2.6 $118.72 2/15/20253,040,000 shares $349.66 million +26.7%3.2%2.6 $115.02 1/31/20252,400,000 shares $364.37 million -25.0%N/A2.1 $151.82 1/15/20253,200,000 shares $456.19 million -4.5%N/A3.2 $142.56 12/31/20243,350,000 shares $457.28 million -1.2%N/A3.5 $136.50 12/15/20243,390,000 shares $429.51 million -13.3%N/A3.6 $126.70 11/30/20243,910,000 shares $495.59 million -7.8%N/A4.3 $126.75 11/15/20244,240,000 shares $497.95 million +71.0%N/A4.1 $117.44 10/31/20242,480,000 shares $298.27 million -5.3%N/A2.6 $120.27 Get the Latest News and Ratings for NBIX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. 10/15/20242,620,000 shares $307.43 million +6.9%N/A2.8 $117.34 9/30/20242,450,000 shares $282.29 million +9.9%N/A2.7 $115.22 9/15/20242,230,000 shares $272.62 million +4.2%N/A2.5 $122.25 8/31/20242,140,000 shares $271.91 million -6.6%N/A2.4 $127.06 8/15/20242,290,000 shares $338.39 million -14.2%N/A2.9 $147.77 7/31/20242,670,000 shares $377.99 million +1.5%N/A3.4 $141.57 7/15/20242,630,000 shares $387.82 million -6.7%N/A3.4 $147.46 6/30/20242,820,000 shares $388.23 million +26.5%N/A3.6 $137.67 6/15/20242,230,000 shares $302.05 million +4.7%N/A2.8 $135.45 5/31/20242,130,000 shares $288.42 million +14.5%N/A2.6 $135.41 5/15/20241,860,000 shares $264.12 million +1.6%N/A2.2 $142.00 4/30/20241,830,000 shares $251.70 million -9.4%N/A2.1 $137.54 4/15/20242,020,000 shares $266.11 million -16.9%N/A2.3 $131.74 3/31/20242,430,000 shares $335.15 million -2.0%N/A2.8 $137.92 3/15/20242,480,000 shares $344.97 million +13.8%N/A2.9 $139.10 2/29/20242,180,000 shares $284.27 million No ChangeN/A2.6 $130.40 2/15/20242,180,000 shares $292.12 million +16.0%N/A2.7 $134.00 1/31/20241,880,000 shares $262.77 million -18.6%N/A2.4 $139.77 1/15/20242,310,000 shares $304.99 million +1.8%N/A3.1 $132.03 12/31/20232,270,000 shares $299.10 million -0.4%N/A3.2 $131.76 12/15/20232,280,000 shares $274.10 million +8.1%N/A3.2 $120.22 11/30/20232,110,000 shares $246.00 million -7.5%N/A3.1 $116.59 11/15/20232,280,000 shares $252.42 million +2.2%N/A3.4 $110.71 10/31/20232,230,000 shares $247.40 million +1.8%N/A3.4 $110.94 10/15/20232,190,000 shares $247.12 million +18.4%N/A3.2 $112.84 9/30/20231,850,000 shares $208.13 million -8.4%N/A2.6 $112.50 9/15/20232,020,000 shares $227.15 million No ChangeN/A2.8 $112.45 8/31/20232,020,000 shares $219.96 million +3.6%N/A2.6 $108.89 8/15/20231,950,000 shares $207.32 million -3.9%N/A2.6 $106.32 7/31/20232,030,000 shares $206.84 million -12.9%N/A2.7 $101.89Ex CIA predicts 40% “double crash” – April 11 (Ad)The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… They’re studying something far more alien… Something you’ve never seen before…Click here for my latest prediction before it’s taken offline. 7/15/20232,330,000 shares $221.61 million -3.7%N/A3.1 $95.11 6/30/20232,420,000 shares $228.21 million -5.1%N/A3.3 $94.30 6/15/20232,550,000 shares $246.97 million -1.9%N/A3.5 $96.85 5/31/20232,600,000 shares $232.78 million -6.8%N/A3.7 $89.53 5/15/20232,790,000 shares $273.84 million +5.7%N/A4 $98.15 4/30/20232,640,000 shares $266.75 million +3.5%N/A3.5 $101.04 4/15/20232,550,000 shares $262.09 million -7.6%N/A3.4 $102.78 3/31/20232,760,000 shares $279.37 million +3.4%N/A3.4 $101.22 3/15/20232,670,000 shares $251.27 million +5.1%N/A3.4 $94.11 2/28/20232,540,000 shares $261.87 million -1.6%N/A3.2 $103.10 2/15/20232,580,000 shares $267.62 million -1.2%N/A3.3 $103.73 1/31/20232,610,000 shares $289.53 million +0.8%2.8%3.2 $110.93 1/15/20232,590,000 shares $282.28 million +15.1%2.8%3.2 $108.99 12/30/20222,250,000 shares $268.74 million +0.5%2.4%2.8 $119.44 12/15/20222,240,000 shares $261.39 million -16.7%2.4%2.7 $116.69 11/30/20222,690,000 shares $341.79 million -5.3%2.9%3.3 $127.06 11/15/20222,840,000 shares $325.95 million +8.0%3.0%3.5 $114.77 10/31/20222,630,000 shares $302.77 million -4.0%2.8%3.3 $115.12 10/15/20222,740,000 shares $296.55 million +3.0%2.9%3.6 $108.23 9/30/20222,660,000 shares $282.52 million +10.4%2.8%3.6 $106.21 9/15/20222,410,000 shares $257.70 million +11.6%2.6%3.4 $106.93 8/31/20222,160,000 shares $226.00 million -21.7%2.3%3 $104.63 8/15/20222,760,000 shares $296.40 million +7.0%3.0%3.7 $107.39 7/31/20222,580,000 shares $242.86 million -0.8%2.8%3.3 $94.13 7/15/20222,600,000 shares $247.44 million +5.3%2.8%3.4 $95.17 6/30/20222,470,000 shares $240.78 million -33.8%2.6%3.2 $97.48 6/15/20223,730,000 shares $347.45 million +4.2%4.2%5 $93.15 5/31/20223,580,000 shares $334.69 million -17.1%3.8%4.9 $93.49 5/15/20224,320,000 shares $363.40 million +23.1%4.6%6.1 $84.12 4/30/20223,510,000 shares $316.01 million +7.7%3.8%4.6 $90.03 4/15/20223,260,000 shares $323.62 million +9.8%3.5%4.4 $99.27 3/31/20222,970,000 shares $278.44 million +1.0%3.2%3.5 $93.75 3/15/20222,940,000 shares $267.72 million +2.4%3.2%3.5 $91.06 2/28/20222,870,000 shares $257.93 million +3.2%3.1%3.2 $89.87 2/15/20222,780,000 shares $240.44 million -2.5%3.0%3 $86.49 1/31/20222,850,000 shares $225.21 million +13.1%3.1%3.2 $79.02 1/15/20222,520,000 shares $197.47 million -10.6%2.7%2.8 $78.36 12/31/20212,820,000 shares $240.18 million -4.7%3.1%3.4 $85.17 12/15/20212,960,000 shares $250.59 million +8.4%3.2%3.8 $84.66 11/30/20212,730,000 shares $227.27 million -13.9%3.0%3.7 $83.25 11/15/20213,170,000 shares $278.26 million -14.1%3.4%5 $87.78 10/29/20213,690,000 shares $388.96 million +2.2%4.0%5.9 $105.41 10/15/20213,610,000 shares $377.39 million +4.3%3.9%5.9 $104.54 9/30/20213,460,000 shares $331.85 million -0.9%3.8%5.6 $95.91 9/15/20213,490,000 shares $336.23 million -6.7%3.8%5.3 $96.34 8/31/20213,740,000 shares $356.05 million +4.8%4.1%5.6 $95.20 8/13/20213,570,000 shares $318.16 million -13.6%3.9%4.8 $89.12 7/30/20214,130,000 shares $384.96 million +3.0%4.5%5.5 $93.21 7/15/20214,010,000 shares $376.06 million -8.5%4.3%5.6 $93.78 6/30/20214,380,000 shares $426.26 million -1.1%4.7%6 $97.32Ex CIA predicts 40% “double crash” – April 11 (Ad)The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… They’re studying something far more alien… Something you’ve never seen before…Click here for my latest prediction before it’s taken offline. 6/15/20214,430,000 shares $433.65 million -13.5%4.8%4.1 $97.89 5/28/20215,120,000 shares $492.65 million -3.8%5.5%4.7 $96.22 5/14/20215,320,000 shares $489.07 million -11.6%N/A4.7 $91.93 4/30/20216,020,000 shares $573.89 million -3.2%N/A5.1 $95.33 4/15/20216,220,000 shares $591.21 million -11.1%N/A5.3 $95.05 3/31/20217,000,000 shares $659.82 million +57.3%N/A5.6 $94.26 3/15/20214,450,000 shares $431.92 million +18.7%N/A5.1 $97.06 2/26/20213,750,000 shares $400.54 million -7.4%N/A4.2 $106.81 2/12/20214,050,000 shares $467.41 million -1.2%N/A4.5 $115.41 1/29/20214,100,000 shares $458.91 million -6.2%N/A4.1 $111.93 1/15/20214,370,000 shares $477.60 million No ChangeN/A4.5 $109.29 12/31/20204,370,000 shares $417.16 million +1.4%N/A4.8 $95.46 12/15/20204,310,000 shares $402.81 million -7.9%N/A4.7 $93.46 11/30/20204,680,000 shares $447.22 million -3.1%N/A4.9 $95.56 11/15/20204,830,000 shares $444.26 million -5.7%N/A5.1 $91.98 10/30/20205,120,000 shares $506.47 million +1.8%N/A6.1 $98.92 10/15/20205,030,000 shares $508.18 million -2.1%N/A6.4 $101.03 9/30/20205,140,000 shares $494.26 million -9.4%N/A6.4 $96.16 9/15/20205,670,000 shares $591.38 million +3.5%N/A7.1 $104.30 8/31/20205,480,000 shares $637.98 million +3.6%N/A7 $116.42 8/14/20205,290,000 shares $605.12 million -6.2%N/A6.7 $114.39 7/31/20205,640,000 shares $678.83 million +12.6%N/A6.5 $120.36 7/15/20205,010,000 shares $656.91 million +3.9%N/A5.8 $131.12 6/30/20204,820,000 shares $604.91 million +4.1%N/A5.6 $125.50 6/15/20204,630,000 shares $533.98 million -1.9%N/A5.5 $115.33 5/29/20204,720,000 shares $588.87 million -2.3%N/A5.3 $124.76 5/15/20204,830,000 shares $562.70 million -5.1%N/A5.4 $116.50 4/30/20205,090,000 shares $499.53 million -2.7%N/A6.3 $98.14 4/15/20205,230,000 shares $497.53 million +3.0%N/A6.5 $95.13 3/31/20205,080,000 shares $498.75 million -1.0%5.6%6.1 $98.18 NBIX Short Interest - Frequently Asked Questions What is Neurocrine Biosciences' current short interest? Short interest is the volume of Neurocrine Biosciences shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 3,290,000 shares of NBIX short. 3.45% of Neurocrine Biosciences' shares are currently sold short. Learn More on Neurocrine Biosciences' current short interest. What is a good short interest ratio for Neurocrine Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NBIX shares currently have a short interest ratio of 2.0. Learn More on Neurocrine Biosciences's short interest ratio. Which institutional investors are shorting Neurocrine Biosciences? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Neurocrine Biosciences: GTS Securities LLC, Squarepoint Ops LLC, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC , Millennium Management LLC, LMR Partners LLP, J. Goldman & Co LP, Citadel Advisors LLC, Jane Street Group LLC, Susquehanna International Group LLP, HAP Trading LLC, Concourse Financial Group Securities Inc., Walleye Trading LLC, JPMorgan Chase & Co., and Twin Tree Management LP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Neurocrine Biosciences? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.45% of Neurocrine Biosciences' floating shares are currently sold short. Is Neurocrine Biosciences' short interest increasing or decreasing? Neurocrine Biosciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 3,290,000 shares, an increase of 1.9% from the previous total of 3,230,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Neurocrine Biosciences' short interest compare to its competitors? 3.45% of Neurocrine Biosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Neurocrine Biosciences: Alnylam Pharmaceuticals, Inc. (1.99%), Biogen Inc. (2.27%), United Therapeutics Co. (4.15%), BioMarin Pharmaceutical Inc. (2.55%), Incyte Co. (3.33%), Exelixis, Inc. (4.85%), Repligen Co. (7.17%), Exact Sciences Co. (5.81%), Halozyme Therapeutics, Inc. (8.25%), Madrigal Pharmaceuticals, Inc. (24.29%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Neurocrine Biosciences stock? Short selling NBIX is an investing strategy that aims to generate trading profit from Neurocrine Biosciences as its price is falling. NBIX shares are trading down $0.45 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Neurocrine Biosciences? A short squeeze for Neurocrine Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NBIX, which in turn drives the price of the stock up even further. How often is Neurocrine Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBIX, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies ALNY Short Interest BIIB Short Interest UTHR Short Interest BMRN Short Interest INCY Short Interest EXEL Short Interest RGEN Short Interest EXAS Short Interest HALO Short Interest MDGL Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NBIX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts